GT Biopharma Strengthens Leadership Team
GT Biopharma, Inc. (NASDAQ: GTBP), a cutting-edge clinical stage immuno-oncology company, is excited to announce a new development in its governance team. Hilary Kramer has been appointed to the company's Board of Directors, taking over the position previously held by Bruce Wendel, who has decided to step down. This strategic move comes as GT Biopharma continues its vital work in developing novel therapeutics aimed at harnessing the body’s immune system to fight cancer.
Expertise Behind the Appointment
Michael Breen, who serves as the Executive Chairman and CEO of GT Biopharma, expressed his enthusiasm about Mrs. Kramer's joining the board. He highlighted her extensive experience and operational acumen, which will be invaluable as the company progresses to its next significant phase of growth. Given the current trajectory of clinical advancements, having someone of Mrs. Kramer's caliber on board is a significant advantage for the team.
Hilary Kramer's Impressive Background
Mrs. Kramer is not just a newcomer but is an influential figure in the investment sector. As the Founder and Chief Investment Officer of GreenTech Research, she has pioneered sustainable fund management and has an impressive track record in growth equity research and market forecasting. Her expertise in managing portfolio strategies, allocations, and risk mitigation makes her a pivotal addition to GT Biopharma's governance.
Contributions from Prior Experience
With a history of board service in numerous public companies, including RSL Communications Ltd., and Deltathree Inc., Mrs. Kramer brings a wealth of experience. Her previous role as Senior Managing Director and Chief Investment Officer at a significant family office portfolio involved managing diversified equity and fixed-income portfolios, enhancing her financial strategic vision.
About GT Biopharma's Vision
GT Biopharma is dedicated to pioneering immuno-oncology products derived from its proprietary TriKE® NK cell engager platform. This innovative approach aims to significantly bolster the immune system’s natural ability to destroy cancer cells. The company operates under an exclusive worldwide license agreement with a major university, providing a robust foundation for the further development and commercialization of its advanced therapies.
Looking Ahead
As GT Biopharma continues to innovate and advance its therapies, the addition of Hilary Kramer to its Board of Directors symbolizes a strong commitment to growth and excellence in the biopharmaceutical sector. The company is poised for breakthroughs that could change the landscape of cancer treatment and patient care.
Frequently Asked Questions
What is GT Biopharma's main focus?
GT Biopharma focuses on developing innovative immuno-oncology therapeutic products aimed at enhancing the body's natural killer cells to fight cancer.
Who is the new board member of GT Biopharma?
Hilary Kramer has been appointed to the Board of Directors, taking over from Bruce Wendel.
What experience does Hilary Kramer bring?
Hilary Kramer has an extensive background in investment management, having founded GreenTech Research and held various positions on the boards of several public companies.
What is the TriKE® platform?
The TriKE® platform is a proprietary technology developed by GT Biopharma that enhances the abilities of the immune system's natural killer cells to target and destroy cancer cells.
How can I learn more about GT Biopharma?
For more information about GT Biopharma, you can visit their official website at gtbiopharma.com.
